Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

The annual meeting of the American College of Physicians (Internal Medicine Meeting) was held from April 3 to 5 in New ...

The study, led by Dr. Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that manufacture tirzepatide, is a continuation of the SURMOUNT-1 phase 3 trial ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...

HealthDay News — After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes ...

“Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be sustained for up to three years,” Dr. Busetto noted. He added, “Regardless of age, BMI, and ...

This post hoc analysis of the SURMOUNT-1 study, at three years, aimed to assess weight regain from nadir weight over three years (36 months / 176 weeks) with tirzepatide treatment. Weight regain ...

Discover Mounjaro Tirzepatide's impact on obesity in India post its March launch. Get insights on effectiveness against diabetes, hypertension & more.

Now, there may be another option for him. It's a drug called tirzepatide, also known as Mounjaro or Zepbound. It's FDA approved to manage diabetes and obesity. Now, UC San Diego researchers have ...

Use of newer medications for weight loss and blood sugar management has surged between 2021 and 2023, especially tirzepatide, which is sold under the brand name Mounjaro for diabetes treatment and ...

Consistent with known effects of GLP-1/GIP therapy, over 50% of lost weight was regained within two weeks of stopping treatment in both the tirzepatide and co-administration arms of the study.